2017 | 2016 | 2015 | 2014
DateTitle 
08/01/17INC Research and inVentiv Health Announce Successful Completion of Merger
Combination Creates the Only Fully Integrated Biopharmaceutical Solutions Organization with Combined Net Revenue of More Than $3 Billion Relaunch Under New Brand Planned for 2018 RALEIGH, N.C. and BOSTON, Aug. 01, 2017 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading global Phase I-IV Contract Research Organization (“CRO”), and inVentiv Health, Inc., a leading, privately held global CRO and Contract Commercial Organization (“CCO”), today announced the successful compl... 
Printer Friendly Version
07/27/17INC Research Reports Second Quarter 2017 Results
Highlights Book-to-bill ratio of 1.6x, 1.5x, and 1.4x for the three-, six-, and twelve-month periods ended June 30, 2017, respectively. Net new business awards of $423.8 million and $783.8 million for the three and six months ended June 30, 2017, representing growth of 40.3% and 29.7%, respectively, representing another record quarter of net awards. Net service revenue of $258.1 million and $510.2 million for the three and six months ended June 30, 2017, respectively. GAAP diluted ... 
Printer Friendly Version
07/10/17INC Research Schedules Second Quarter 2017 Earnings Call for Thursday, July 27, 2017
RALEIGH, N.C., July 10, 2017 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading, global Phase I to IV contract research organization, will release its second quarter 2017 financial results on Thursday, July 27, 2017, prior to its quarterly earnings call at 8:00 a.m. EDT. Participants may access the conference call live via webcast on the Investor Relations section of the INC Research website at investor.incresearch.com. To participate via telephone, please dial +1 877 93... 
Printer Friendly Version
07/05/17INC Research Further Expands Catalyst Program with Launch of Psychiatry Catalyst Site Network
Therapeutically-aligned network offers high-performing sites in psychiatry research the opportunity to conduct more trials; enhances high quality delivery for biopharmaceutical customers RALEIGH, N.C., July 05, 2017 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading, global Phase I to IV contract research organization, today announced the launch of the Company’s Psychiatry Catalyst Site Network as part of its Catalyst program introduced in 2016 to strengthen collaboratio... 
Printer Friendly Version
06/28/17INC Research Grows Presence in Japan with Office Expansion and Relocation
New office will allow for global CRO to continue to support rapid growth in Asia/Pacific’s largest pharmaceutical market RALEIGH, N.C., June 28, 2017 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading, global Phase I to IV contract research organization (CRO), today announced the expansion and relocation of its Tokyo, Japan office in support of the Company’s long-term growth strategy both in Japan and across the Asia/Pacific region. In the last two and a half years, I... 
Printer Friendly Version
06/14/17INC Research to Lead the Conversation on ICH E6 R2 Preparedness at DIA 2017 Annual Meeting
Global CRO sharing key insights on the industry’s most pressing drug development topics,  hosting annual Site Appreciation Reception to recognize invaluable work of clinical research sites RALEIGH, N.C., June 14, 2017 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading global Phase I to IV contract research organization, today announced an extensive presence at the DIA 2017 53rd Annual Meeting being held June 18-22 in Chicago, Illinois. INC Research thought leaders will b... 
Printer Friendly Version
06/06/17INC Research Announces 2017 “INCSights” Webinar Series to Advance Dialogue on Clinical Research
Industry experts to host webinar series exploring key issues and trends in clinical research development RALEIGH, N.C., June 06, 2017 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading global Phase I to IV contract research organization, today announced its 2017 INCSights webinar series exploring the latest trends and hot topics in clinical research. The series, featuring INC experts and industry thought leaders, will provide valuable and practical knowledge on a range o... 
Printer Friendly Version
05/31/17INC Research to Present at Upcoming Jefferies Global Healthcare Conference
RALEIGH, N.C., May 31, 2017 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading global Phase I to Phase IV contract research organization, today announced that Chief Executive Officer Alistair Macdonald is scheduled to present at the 2017 Jefferies Global Healthcare Conference in New York, NY.  Mr. Macdonald’s presentation is scheduled for Wednesday, June 7, 2017, at 11 a.m. EDT. Links to INC Research’s live presentation and archived audio replay, as well as the present... 
Printer Friendly Version
05/10/17INC Research and inVentiv Health to Merge
Creates a Leading Global Biopharmaceutical Solutions Organization with Combined Net Revenue of More Than $3.2 Billion Combined Company Will Be Second Largest Biopharmaceutical Outsourcing Provider, One of the Top 3 Contract Research Organizations and the Largest Contract Commercial Organization by Net Revenue Comprehensive Suite of End-To-End Solutions to Support Development and Commercialization of Biopharmaceutical Compounds and Biologics Complementary and Diversified Customer Base with L... 
Printer Friendly Version
05/10/17INC Research Reports First Quarter 2017 Results
Highlights Book-to-bill ratio of 1.4x for the first quarter of 2017 and 1.2x for the twelve-month period ended March 31, 2017. Net new business awards of $359.9 million for the three months ended March 31, 2017, representing growth of 19.0% and the highest quarter of net awards in the Company's history. Net service revenue of $252.1 million for the three months ended March 31, 2017. GAAP diluted earnings per share of $0.38 for the three months ended March 31, 2017. Adjusted di... 
Printer Friendly Version
05/04/17INC Research recognized by CSO Magazine for Second Consecutive Year for Innovative Employee Cyber Security Training Program
CRO recognized for innovative data security employee training strategy that continues to evolve to meet the changing needs of a global organization RALEIGH, N.C., May 04, 2017 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading, global Phase I to IV contract research organization, today announced it has been named to the 2017 CSO50 by IDG’s CSO magazine.  The annual CSO50 Awards recognize organizations (and the people within them) for security projects or initiatives that... 
Printer Friendly Version
05/04/17INC Research and CISCRP Celebrate Clinical Trials Awareness Week through Release of New Educational Animation
Animation reinforces the importance of clinical trials, encourages viewers to think about where new medicines come from and what the world would be like without the people/processes that help bring them to market RALEIGH, N.C., May 04, 2017 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading, global Phase I to IV contract research organization, together with the Center for Information and Study on Clinical Research Participation (CISCRP), a non-profit organization dedicat... 
Printer Friendly Version
04/25/17INC Research is the First CRO to obtain IAOCR’s Silver Workforce Quality Accreditation Status
Accreditation demonstrates continued commitment to implementing business processes that foster the development of a highly-skilled clinical research workforce to deliver on customer needs. RALEIGH, N.C., April 25, 2017 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading global Phase I to IV contract research organization, and IAOCR, the accrediting organization for the international clinical research industry, today announced INC Research has achieved the “Silver Standard... 
Printer Friendly Version
04/20/17INC Research Schedules First Quarter 2017 Earnings Call for Wednesday, May 10, 2017
RALEIGH, N.C., April 20, 2017 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading, global Phase I to IV contract research organization, will release its first quarter 2017 financial results on Wednesday, May 10, 2017, prior to its quarterly earnings call at 8:00 a.m. EDT. Participants may access the conference call live via webcast on the Investor Relations section of the INC Research website at investor.incresearch.com. To participate via telephone, please dial +1 877 ... 
Printer Friendly Version
04/06/17INC Research Bolsters Support for Vaccine Trials through Expanded Site and Patient Initiatives
Company demonstrates continued commitment to vaccine research through donation to the Greater Gift Initiative, celebrates “Best CRO” nomination at World Vaccine Congress 2017 RALEIGH, N.C., April 06, 2017 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading global Phase I to IV contract research organization, will demonstrate its continued commitment and active involvement in vaccine research with an extensive presence at the 17th World Vaccine Congress, April 10-12 in Was... 
Printer Friendly Version
04/03/17INC Research Ranked “Top CRO to Work With” Among Top 10 Global CROs for Third Consecutive Time in Biannual CenterWatch Survey
Survey ranking reinforces Company’s industry-leading position as CRO of Choice for sites Only company to rank consistently among top three CROs in every survey over the last decade Company rated a top three CRO on all 37 individual relationship attributes noted as important to sites RALEIGH, N.C., April 03, 2017 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading, global Phase I to IV contract research organization, is ranked “Top CRO to Work With” among the top 10 glob... 
Printer Friendly Version
03/30/17INC Research Strengthens Real World & Late Phase and Global Consulting Capabilities with Key Leadership Appointments
Additional senior-level expertise enhances global CRO’s strategic services offering, helping large pharma to meet their commercial objectives while strongly positioning the Company to capitalize on this growing market opportunity RALEIGH, N.C., March 30, 2017 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading global Phase I to IV contract research organization, today announced it has appointed several new senior leaders to strengthen its Real World & Late Phase (RWLP... 
Printer Friendly Version
03/03/17INC Research Appoints William E. Klitgaard and Linda S. Harty to Board of Directors
Klitgaard and Harty bring extensive IT and finance experience to guide the Company’s growth RALEIGH, N.C., March 03, 2017 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading global Phase I to IV contract research organization, today announced the appointment of William E. Klitgaard and Linda S. Harty to the Company’s Board of Directors effective immediately. Mr. Klitgaard previously was President of Enlighten Health, a division of LabCorp, a world healthcare diagnostics c... 
Printer Friendly Version
02/28/17INC Research Reports Fourth Quarter and Full Year 2016 Results
Highlights  Book-to-bill ratio of 1.1x and 1.2x for the fourth quarter and full year 2016, respectively. Net new business awards of $289.6 million and $1.22 billion for the fourth quarter and full year 2016, respectively. Net service revenue of $263.0 million for the fourth quarter, representing growth of 9.0%, and $1,030.3 million for the full year 2016, representing growth of 12.6%. GAAP diluted earnings per share of $0.68 and $2.03 for the fourth quarter and full yea... 
Printer Friendly Version
02/22/17INC Research Expands Functional Service Provider Services Through New Investigator Payment Offering
New service leverages Company’s extensive expertise in investigator payment processing, innovative cloud payment technology through Medidata and builds on extensive FSP capabilities RALEIGH, N.C., Feb. 22, 2017 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading global Phase I to IV contract research organization, today announced expansion of its Functional Service Provider (FSP) service offering to include investigator payment processing, leveraging  the Company’s extens... 
Printer Friendly Version
02/08/17INC Research Further Strengthens Board of Directors Through Appointment of Pharmaceutical Executive Eric P. Pâques
RALEIGH, N.C., Feb. 08, 2017 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading global Phase I to IV contract research organization, today announced the appointment of Eric Paul Pâques, previously the Chief Executive Officer for GRÜNENTHAL GROUP, to the Company’s Board of Directors.  Mr. Pâques joins the INC Research Board as an independent director and will be a Class I director serving a term ending at the Company’s 2018 Annual Meeting. “We are pleased to welcome Eri... 
Printer Friendly Version
02/06/17INC Research Schedules Fourth Quarter and Year End 2016 Earnings Call for Tuesday, February 28, 2017
RALEIGH, N.C., Feb. 06, 2017 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading, global Phase I to IV contract research organization, will release its fourth quarter and full year 2016 financial results on Tuesday, February 28, 2017, prior to its quarterly earnings call at 8:00 a.m. EST. Participants may access the conference call live via webcast on the Investor Relations section of the INC Research website at investor.incresearch.com. To participate via telephone, pl... 
Printer Friendly Version